secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-08-13T11:42:49+00:00
Accession:  0001193125-26-347911
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q2 net loss $25.3M; $50M private placement extends cash runway into Q2 2027
--------------------------------------------------------------------------------

- Net loss $25.3M ($0.40/share) vs $18.4M ($0.30) in Q2 2025; R&D $16.1M, G&A $9.9M.
- Completed July 2, 2026 private placement: ~$50M upfront gross, up to $64M more if warrants exercised.
- Cash, equivalents, restricted cash, and short-term investments $34.5M at June 30, 2026; runway into Q2 2027.
- MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC expected Fall 2026; pembrolizumab combo update Q4 2026.
- Interim CEO Tom Civik cites financing and clinical execution; shares outstanding 83.4M as of Aug 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/0001193125-26-347911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/pyxs-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer